Building on the extraordinary success of its platform in producing an effective coronavirus vaccine, German mRNA specialist BioNTech is making inroads on a proj 2 June 2023
As the crowds descend on Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO), The Pharma Letter interviews Eisai chief medical of 1 June 2023
This year’s meeting of the American Society of Clinical Oncology (ASCO) kicks off on Friday, with the highly anticipated plenary session taking place on Sunday. 31 May 2023
In the runup to this year’s meeting of the American Society of Clinical Oncology (ASCO), drugmakers around the world are lifting the curtain on the data they pl 31 May 2023
Positive data for a new kind of cancer med, targeting the CLDN18.2 biomarker, will be presented at the March Plenary Series of the American Society of Clinical 22 March 2023
Dostarlimab, an anti–PD-1 monoclonal antibody marketed by GSK under the brand name Jemperli, has shown impressive results in mismatch repair–deficient stage II 7 June 2022
Even as generic competition gathers, the treatment landscape in multiple myeloma will likely be dominated by Bristol Myers Squibb’s Revlimid (lenalidomide) for 7 June 2022
The Johnson & Johnson subsidiary Janssen has presented data in multiple myeloma and mantle cell lymphoma at the 2022 American Society of Clinical Oncology (ASCO 6 June 2022
Bristol Myers Squibb has presented two lots of data on its immunotherapy combination of Opdivo (nivolumab)plus Yervoy (ipilimumab) at the 2022 American Society 6 June 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.